Cell and gene therapy companies develop advanced treatments that modify, replace or engineer cells and genetic material to treat disease. The field is one of the fastest-growing areas of biotechnology and precision medicine.
This category includes companies working on:
Browse 163 UK cell and gene therapy companies below.
Cell and gene therapy CDMO specialising in ATMP development and manufacturing
Adthera Bio is a contract development and manufacturing organisation focused exclusively on cell and gene therapy advanced therapy medicinal products. The company provides GMP-compliant process development, analytical development, and manufacturing services to biotech and academic partners. Operating from…
AI-native platform for cell culture process design and optimisation
Tolemy Bio Ltd is a company developing an AI-native platform for cell therapy process development and manufacturing optimisation. The platform ingests experimental and bioreactor data including cell growth, phenotype, potency, and metabolite profiles, then applies causal AI models to identify the biological drivers of…
Chromatography resins and bioseparation technologies for biomanufacturing
Astrea Bioseparations develops and manufactures chromatography resins, adsorbents, columns and nanofiber-based purification technologies for the biopharmaceutical and advanced therapeutics industries. Its portfolio supports downstream bioprocessing including affinity purification, host cell protein removal, viral…
Multimodal engineered T-cell therapies for treatment-refractory solid cancers
Alceus Bio is a biotechnology company developing next-generation engineered T-cell therapies for solid tumours. Its platform uses generative AI and synthetic biology to design therapeutic proteins that patient-derived immune cells are programmed to express and deliver in situ, targeting intracellular disease drivers…
CAR-T and bispecific antibody therapies for blood cancers
Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for haematological malignancies and autoimmune diseases. Its lead asset, HG-CT-1, is a third-generation anti-FLT3 CAR-T cell therapy for relapsed and refractory acute myeloid leukaemia, currently in a Phase 1…
siRNA gene therapies targeting root causes of ALS and frontotemporal dementia
Crucible Therapeutics Limited is a preclinical-stage biotechnology company developing siRNA-based gene therapies for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia caused by the C9orf72 gene mutation. Its therapeutic approach depletes the SRSF1 protein to suppress production of toxic dipeptide repeat…
Allogeneic neutrophil cell therapy platform for solid tumours
LIfT BioSciences is a biotechnology company developing a first-in-class allogeneic neutrophil immunotherapy for the treatment of solid tumours. Its platform produces Immuno-Modulatory Alpha Neutrophils (IMANs) from donor haematopoietic or induced pluripotent stem cells using a proprietary enhancement process. IMANs…
Engineered iPSC-derived exosomes for tissue-targeted drug delivery
Excellio Labs is a biotech developing engineered exosome platforms for targeted drug delivery. The technology exploits the inherent tissue-specificity of iPSC-derived extracellular vesicles, which are further surface-modified to create precision drug carriers capable of delivering nucleic acids, proteins, and small…
Full-service CRO delivering clinical trials, regulatory and pharmacovigilance services
ProPharma is a contract research organisation providing full-service clinical trial delivery alongside regulatory affairs, pharmacovigilance, quality and compliance, and medical information services to pharmaceutical, biotechnology and medical device companies. The company supports clinical operations, site and…
Off-the-shelf cell therapies for cancer and rare diseases
Empyrean Therapeutics develops off-the-shelf cell therapies intended to make treatments for cancer and rare diseases more accessible. Its approach combines gene editing, stem cell programming and precise genetic control to engineer therapeutic cells. The company is developing cell platforms and manufacturing processes…
In vivo immune cell reprogramming for autoimmune and inflammatory disease
Flip Therapeutics is a biotechnology company developing in vivo immune cell engineering therapies for chronic autoimmune and inflammatory diseases, including multiple sclerosis, type 1 diabetes and inflammatory bowel disease. The company reprograms pathogenic T cells into homeostatic, anti-inflammatory cells directly…
Cell culture media, reagents, and instruments for life sciences
STEMCELL Technologies UK is the British subsidiary of STEMCELL Technologies Canada Inc., a privately held Canadian biotechnology company founded in 1993. The Cambridge facility serves as the company's European hub for sales, marketing, research and development, and customer training, supporting researchers across the…
Engineered T-regulatory cell therapies for immune-mediated diseases
Quell Therapeutics is a clinical-stage UK biotech developing engineered T-regulatory (Treg) cell therapies for immune-mediated diseases, using its proprietary technology to engineer Tregs with enhanced persistence and potency. Its lead candidate QEL-001 is in the Phase 1/2 LIBERATE trial for liver transplant…
Autologous platelet-based biotherapies for chronic wound healing
Biotherapy Services is a clinical-stage company developing autologous biotherapies for wound healing and tissue regeneration. Its lead treatment is a gel prepared at the point of care from a concentrate of the patient's own platelets, activated with the patient's own thrombin to release growth factors and other…
Engineered therapeutic red blood cells for rare metabolic and other diseases
Scarlet Therapeutics is a biotechnology company developing a platform for generating therapeutic red blood cells (tRBCs). Erythroid cell lines are genetically engineered to produce red blood cells carrying high concentrations of therapeutic proteins, exploiting their natural tissue distribution, 120-day circulating…
Lentiviral vector platform improving yield for advanced cell therapies
Lentitek is a biotechnology company developing proprietary lentiviral vector manufacturing technology for cell and gene therapy developers. Its platform uses novel promoter engineering to reduce unwanted payload gene expression in manufacturing cell lines, improving vector yield, quality and potency. The technology…
AI live cell imaging platform for stem cell therapy development
CellVoyant is a biotech developing AI-powered live cell imaging and process optimisation platforms for stem cell therapy development. The technology uses computer vision and neural network models to predict stem cell differentiation behaviour in real time, without destructive sampling, enabling earlier and more…
Contract development and manufacture of nanofibrous biomaterials for medical devices
The Electrospinning Company designs, develops, and manufactures nanofibrous biomaterials for implantable medical devices and regenerative medicine applications. Using electrospinning technology, the company produces four proprietary membrane platforms: resorbable Mimetix, permanent Kalyptix, biosynthetic Symatix, and…
Global biologics CDMO for vaccines, antibodies, and advanced therapies
FUJIFILM Biotechnologies is a contract development and manufacturing organisation providing process development and cGMP manufacturing of biologics, vaccines, and cell and gene therapies. Its UK site at Billingham, Teesside, includes mammalian cell culture and microbial fermentation facilities, with the UK's largest…
AI bioprocess operating system for cell and gene therapy manufacturing
Native Labs Ltd is a software company developing an AI-powered bioprocess operating system for cell and gene therapy manufacturing. The platform unifies heterogeneous manufacturing data, including bioreactor time series, multi-omics, and batch records, into standardised AI-ready datasets. Neural network models enable…